Detalles de la búsqueda
1.
In vitro development of resistance against antipseudomonal agents: comparison of novel ß-lactam/ß-lactamase inhibitor combinations and other ß-lactam agents.
Antimicrob Agents Chemother
; 68(5): e0136323, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526050
2.
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates.
J Antimicrob Chemother
; 76(12): 3125-3134, 2021 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459890
3.
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
J Antimicrob Chemother
; 76(11): 2833-2838, 2021 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34436603
4.
Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018.
Antimicrob Agents Chemother
; 64(2)2020 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31712207
5.
Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum ß-Lactamases from U.S. Hospitals.
Antimicrob Agents Chemother
; 63(7)2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31085510
6.
Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30670418
7.
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
J Antimicrob Chemother
; 74(9): 2588-2595, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31225882
8.
Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
J Clin Microbiol
; 56(12)2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30257898
9.
Correction for Castanheira et al., "Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018".
Antimicrob Agents Chemother
; 64(4)2020 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209562
10.
Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice.
Nat Biotechnol
; 42(2): 265-274, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37142704
11.
Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation.
mSphere
; 8(5): e0016223, 2023 10 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37768064
12.
In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms.
Int J Antimicrob Agents
; 61(1): 106698, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36464152
13.
Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents.
JAC Antimicrob Resist
; 4(5): dlac098, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36196444
14.
The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel ß-lactam/ß-lactamase inhibitor combinations.
J Glob Antimicrob Resist
; 31: 72-79, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35931381
15.
Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients.
JAC Antimicrob Resist
; 3(3): dlab126, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34514403
16.
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Int J Antimicrob Agents
; 58(5): 106439, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34547421
17.
Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents.
JAC Antimicrob Resist
; 3(3): dlab136, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34430873
18.
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.
Microb Drug Resist
; 27(3): 342-349, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762605
19.
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and ß-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Int J Antimicrob Agents
; 56(1): 106011, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32417206
20.
Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms.
Diagn Microbiol Infect Dis
; 98(1): 115077, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32629337